{
  "id": 2906785,
  "title": "Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?",
  "url": "https://urgent.news/2026/08/24/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T00:50:02.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms"
  },
  "original_language": "en",
  "account": "Symbiotec Pharmalab is set to raise capital through an IPO, with plans to issue ₹150 crore for debt repayment and an additional ₹1,607 crore through an offer for sale. This will reduce the promoter group's stake from 36.4% to 33.3%. The company specializes in active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products, with over two-thirds of revenue coming from international markets, particularly Europe.\n\nThe company's valuation appears attractive when compared to its peers. Its global leadership in corticosteroid and steroidal-hormone APIs is evident, with a market share of 38.2% and 23.8% respectively in FY26. This dominance is backed by a backward-integrated platform, backed by approvals from major regulatory bodies worldwide.\n\nAPIs continue to be the primary revenue generator, accounting for more than 96% of total revenue in FY26. However, the company is also venturing into newer areas such as complex injectables and contract manufacturing (CDMO) services. Despite heavy capital expenditure and fluctuations in working capital, the company has seen a steady growth in revenue, annualized at 10.2% from FY24 to FY26. The operating profit, EBITDA, and net profit have also seen positive growth over the same period.\n\nHowever, investors should note that Symbiotec Pharmalab does not have an exact listed peer due to its niche in steroidal hormones and advanced drug-device formulation. Therefore, a price-earnings (P/E) multiple of up to 58 has been suggested for the company. The P/E range for other API or biotechnology manufacturers is between 63 and 110, suggesting that Symbiotec Pharmalab's valuation may be more favorable. Hence, high-risk investors may find this IPO appealing, given the company's market leadership and growth prospects.",
  "summary": "Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this…",
  "key_points": [
    "Symbiotec Pharmalab raising ₹150 crore through IPO for debt repayment",
    "Company specializes in APIs, nutritional ingredients, specialty products",
    "Global leader in corticosteroid and steroidal-hormone APIs with 38.2% market share"
  ],
  "editors_take": "Symbiotec Pharmalab's IPO offers high-risk investors a potentially attractive entry point, given its market leadership, growth prospects, and favorable valuation compared to peers in the API and biotechnology sectors.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Hindu BusinessLine",
        "title": "Symbiotec Pharmalab IPO opens today: Price, dates, lot size and key details",
        "url": "https://urgent.news/2026/08/24/symbiotec-pharmalab-ipo-opens-today-price-dates-lot-size-and-key",
        "published": "2026-08-24T02:27:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}